Potential efficacy of immunosuppressant in the treatment of COVID-19
Chinese Journal of Microbiology and Immunology (China)
; 40(7):505-510, 2020.
Article
in Chinese
| EMBASE | ID: covidwho-701955
ABSTRACT
The outbreak of COVID-19 has infected millions of people and caused hundreds of thousands of deaths worldwide. As there is no specific medicines or effective vaccines against 2019-nCoV at present, it is an alternative strategy to repurpose existing drugs for new diseases. Cyclosporin A inhibits the replication of coronaviruses by binding to cellular cyclophilins. Chloroquine/hydroxychloroquine can block virus-receptor binding through interfering with terminal glycosylation of the cellular receptor angiotensin-converting enzyme 2 (ACE2). Trastuzumab prevents the binding of IL-6 to both sIL-6R and mIL-6R and thereby inhibits the cytokine storm syndrome induced by COVID-19. This paper discussed the potential anti-2019-nCoV effects of some common immunosuppressant including cyclosporine, chloroquine/hydroxychloroquine, and tocilizumab.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Chinese
Journal:
Chinese Journal of Microbiology and Immunology (China)
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS